PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

about

Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer

P2860

Q58772230-D2A33E66-9CC4-47DC-A5C7-0D9D10BF6CED

P2860

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

Item

http://www.wikidata.org/entity/Q48263465

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

@en

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

@nl

type

Item

label

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

@en

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

@nl

prefLabel

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

@en

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

@nl

P1476

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise

@en

P2093

Shaji Kumar

http://www.w3.org/2001/XMLSchema#string

Vijay Ramakrishnan

http://www.w3.org/2001/XMLSchema#string

P2860

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

Initial genome sequencing and analysis of multiple myeloma

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

P304

2524-2534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1421760

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shaji K Kumar

Vijay Ramakrishnan

P577

2018-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29322846

http://www.w3.org/2001/XMLSchema#string

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

about

P2860

P2860

PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698